Monoclonal antibody therapy prevent severe disease, deaths in high-risk individuals : AIG study

Uniindia: Hyderabad Nov 2 (UNI) AIG (Asian Institute of Gastroenterology) Hospitals along with the Asian Healthcare Foundation, Centre for Cellular & Molecular Biology(CCMB) Hyderabad and Institute of Life Sciences, in their study successfully proved that the Monoclonal antibody Therapy reduces severe disease and death in high-risk individuals infected with the Delta Variant of SARS CoV 2 by 100 per cent.

Related Keywords

Delhi ,India ,Hyderabad ,Andhra Pradesh ,Wuhan ,Hubei ,China ,Nageshwar Reddy ,Padma Bhushan ,Donald Trump ,Centre For Cellular Molecular Biology ,Asian Institute Of Gastroenterology Hospitals ,Institute Of Life Sciences ,University Of Hyderabad ,Asian Healthcare Foundation ,Hyderabad Nov ,Asian Institute ,Molecular Biology ,Life Sciences ,Delta Variant ,Monoclonal Antibody ,Monoclonal Therapy ,Wuhan Strain ,Fever Clinic ,Monoclonal ,Antibody ,Therapy ,Prevent ,Severe ,Disease ,Deaths ,In ,Thigh ,Risk ,Individuals , ,Aig ,Study ,